Global vaccine alliance GAVI hopes India will resume exports in July quarter

GAVI co-leads the COVAX facility for equitable distribution of COVID-19 shots around the world. COVAX suffered a big jolt in April when big vaccine producer India stopped all overseas shipments to meet local demand as infections rose dramatically.

Reuters
July 07, 2021 / 11:23 AM IST

GAVI co-leads the COVAX facility for equitable distribution of COVID-19 shots around the world. COVAX suffered a big jolt in April when big vaccine producer India stopped all overseas shipments to meet local demand as infections rose dramatically.

The GAVI vaccine alliance hopes the Serum Institute of India (SII) will resume exports of the AstraZeneca COVID-19 vaccine from this quarter, it told Reuters, which would be earlier than an "end of this year" forecast by the Indian company.

GAVI co-leads the COVAX facility for equitable distribution of COVID-19 shots around the world. COVAX suffered a big jolt in April when big vaccine producer India stopped all overseas shipments to meet local demand as infections rose dramatically.

India's coronavirus crisis has now eased and output of the AstraZeneca drug at SII, the world's biggest vaccine maker, has also jumped, but so has domestic demand.

"We remain hopeful that SII deliveries will resume in the third quarter, however, this cannot be confirmed at this stage," a GAVI spokesperson said in an e-mail late on Tuesday.

"In the meantime, COVAX has been aggressively following through on its strategy of diversifying its portfolio, securing over a billion additional doses in the past month alone either through direct procurements or through dose sharing."

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

SII did not immediately respond to a request for comment. A source close to SII said the company was focused on supplying to India for now. It said in May that it hoped to "start delivering to COVAX and other countries by the end of this year".

India's foreign ministry did not immediately respond to queries from Reuters.

Bangladesh's health minister told reporters on Tuesday that SII could restart supplies to it from August. The country, suffering from a resurgence in infections, has received only 7 million doses out of 30 million it has ordered from the company.
Reuters
Tags: #Business #Companies #Coronavirus. COVID-19 #Gavi #Vccine
first published: Jul 7, 2021 11:25 am